Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.07
CERN's Cash-to-Debt is ranked lower than
67% of the 2082 Companies
in the Global Health Information Services industry.

( Industry Median: 8.37 vs. CERN: 2.07 )
Ranked among companies with meaningful Cash-to-Debt only.
CERN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: 1.34 Max: 10.9
Current: 2.07
0.5
10.9
Equity-to-Asset 0.75
CERN's Equity-to-Asset is ranked higher than
75% of the 1985 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. CERN: 0.75 )
Ranked among companies with meaningful Equity-to-Asset only.
CERN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.64 Max: 0.79
Current: 0.75
0.44
0.79
Debt-to-Equity 0.09
CERN's Debt-to-Equity is ranked higher than
73% of the 1133 Companies
in the Global Health Information Services industry.

( Industry Median: 0.27 vs. CERN: 0.09 )
Ranked among companies with meaningful Debt-to-Equity only.
CERN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.17 Max: 0.43
Current: 0.09
0.04
0.43
Debt-to-EBITDA 0.29
CERN's Debt-to-EBITDA is ranked higher than
78% of the 1031 Companies
in the Global Health Information Services industry.

( Industry Median: 1.33 vs. CERN: 0.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CERN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12  Med: 0.24 Max: 0.49
Current: 0.29
0.12
0.49
Piotroski F-Score: 7
Altman Z-Score: 10.19
Beneish M-Score: -2.79
WACC vs ROIC
9.23%
19.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 17.62
CERN's Operating Margin % is ranked higher than
85% of the 2027 Companies
in the Global Health Information Services industry.

( Industry Median: 4.54 vs. CERN: 17.62 )
Ranked among companies with meaningful Operating Margin % only.
CERN' s Operating Margin % Range Over the Past 10 Years
Min: 16.64  Med: 19.21 Max: 22.43
Current: 17.62
16.64
22.43
Net Margin % 16.50
CERN's Net Margin % is ranked higher than
87% of the 2027 Companies
in the Global Health Information Services industry.

( Industry Median: 3.36 vs. CERN: 16.50 )
Ranked among companies with meaningful Net Margin % only.
CERN' s Net Margin % Range Over the Past 10 Years
Min: 11.26  Med: 13.48 Max: 16.86
Current: 16.5
11.26
16.86
ROE % 18.79
CERN's ROE % is ranked higher than
82% of the 1969 Companies
in the Global Health Information Services industry.

( Industry Median: 6.14 vs. CERN: 18.79 )
Ranked among companies with meaningful ROE % only.
CERN' s ROE % Range Over the Past 10 Years
Min: 13.28  Med: 15 Max: 19.9
Current: 18.79
13.28
19.9
ROA % 13.74
CERN's ROA % is ranked higher than
88% of the 2097 Companies
in the Global Health Information Services industry.

( Industry Median: 3.01 vs. CERN: 13.74 )
Ranked among companies with meaningful ROA % only.
CERN' s ROA % Range Over the Past 10 Years
Min: 9.6  Med: 11 Max: 14.33
Current: 13.74
9.6
14.33
ROC (Joel Greenblatt) % 42.34
CERN's ROC (Joel Greenblatt) % is ranked higher than
63% of the 2065 Companies
in the Global Health Information Services industry.

( Industry Median: 20.86 vs. CERN: 42.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CERN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 42.34  Med: 62.78 Max: 74.95
Current: 42.34
42.34
74.95
3-Year Revenue Growth Rate 16.10
CERN's 3-Year Revenue Growth Rate is ranked higher than
76% of the 1648 Companies
in the Global Health Information Services industry.

( Industry Median: 5.80 vs. CERN: 16.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CERN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 16.1 Max: 29.6
Current: 16.1
5.8
29.6
3-Year EBITDA Growth Rate 14.30
CERN's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 1481 Companies
in the Global Health Information Services industry.

( Industry Median: 8.80 vs. CERN: 14.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CERN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 16.9 Max: 65.1
Current: 14.3
-6.6
65.1
3-Year EPS without NRI Growth Rate 19.70
CERN's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 1387 Companies
in the Global Health Information Services industry.

( Industry Median: 9.80 vs. CERN: 19.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CERN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.6 Max: 99
Current: 19.7
0
99
GuruFocus has detected 2 Warning Signs with Cerner Corp CERN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CERN's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CERN Guru Trades in Q2 2017

Ray Dalio 5,074 sh (New)
Mairs and Power 6,405 sh (New)
Paul Tudor Jones 10,893 sh (New)
Caxton Associates 6,500 sh (New)
PRIMECAP Management 20,000 sh (unchged)
Jeff Auxier 96,255 sh (unchged)
Martin Whitman 372,839 sh (unchged)
Jeremy Grantham Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Third Avenue Management 409,318 sh (-0.19%)
Arnold Van Den Berg 319,686 sh (-2.26%)
Murray Stahl 7,659 sh (-12.57%)
Vanguard Health Care Fund 14,511,817 sh (-12.61%)
Joel Greenblatt 51,095 sh (-75.09%)
Manning & Napier Advisors, Inc 367,371 sh (-79.31%)
» More
Q3 2017

CERN Guru Trades in Q3 2017

Jim Simons 64,704 sh (New)
Joel Greenblatt 190,322 sh (+272.49%)
Steven Cohen 150,000 sh (unchged)
Martin Whitman 372,839 sh (unchged)
Ray Dalio Sold Out
Murray Stahl Sold Out
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Jeff Auxier 96,155 sh (-0.10%)
Third Avenue Management 408,748 sh (-0.14%)
Vanguard Health Care Fund 14,089,017 sh (-2.91%)
PRIMECAP Management 19,400 sh (-3.00%)
Mairs and Power 6,205 sh (-3.12%)
Manning & Napier Advisors, Inc 346,653 sh (-5.64%)
Arnold Van Den Berg 282,314 sh (-11.69%)
» More
Q4 2017

CERN Guru Trades in Q4 2017

John Hussman 60,000 sh (New)
Pioneer Investments 252,789 sh (New)
Steven Cohen 44,937 sh (New)
PRIMECAP Management 19,400 sh (unchged)
Martin Whitman 372,839 sh (unchged)
Arnold Van Den Berg Sold Out
Jim Simons Sold Out
Third Avenue Management Sold Out
Jeff Auxier 95,805 sh (-0.36%)
Vanguard Health Care Fund 12,829,417 sh (-8.94%)
Mairs and Power 5,255 sh (-15.31%)
Joel Greenblatt 129,763 sh (-31.82%)
» More
Q1 2018

CERN Guru Trades in Q1 2018

Jim Simons 1,249,604 sh (New)
Ray Dalio 96,707 sh (New)
Paul Tudor Jones 12,835 sh (New)
Pioneer Investments 273,499 sh (+8.19%)
John Hussman 60,000 sh (unchged)
Jeff Auxier 95,805 sh (unchged)
PRIMECAP Management 19,400 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Martin Whitman Sold Out
Vanguard Health Care Fund 11,669,617 sh (-9.04%)
Mairs and Power 4,455 sh (-15.22%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Reduce -9.04%0.17%$56.51 - $72.9 $ 60.98-6%11,669,617
Joel Greenblatt 2018-03-31 Sold Out 0.13%$56.51 - $72.9 $ 60.98-6%0
Martin Whitman 2018-01-31 Sold Out 2.61%$64.78 - $72.9 $ 60.98-11%0
Vanguard Health Care Fund 2017-12-31 Reduce -8.94%0.19%$64.78 - $73.57 $ 60.98-12%12,829,417
Joel Greenblatt 2017-12-31 Reduce -31.82%0.06%$64.78 - $73.57 $ 60.98-12%129,763
Third Avenue Management 2017-12-31 Sold Out 1.31%$64.78 - $73.57 $ 60.98-12%0
Arnold Van Den Berg 2017-12-31 Sold Out 2.83%$64.78 - $73.57 $ 60.98-12%0
Vanguard Health Care Fund 2017-09-30 Reduce -2.91%0.06%$61.6 - $71.94 $ 60.98-8%14,089,017
Third Avenue Management 2017-09-30 Reduce -0.14%$61.6 - $71.94 $ 60.98-8%408,748
Arnold Van Den Berg 2017-09-30 Reduce -11.69%0.39%$61.6 - $71.94 $ 60.98-8%282,314
Joel Greenblatt 2017-09-30 Add 272.49%0.15%$61.6 - $71.94 $ 60.98-8%190,322
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 519190    SIC: 8099
Compare:NYSE:VEEV, NAS:ATHN, NAS:MDSO, NAS:HQY, SZSE:300253, NYSE:TDOC, XTER:COP, NAS:PINC, NAS:OMCL, NAS:INOV, HKSE:02666, SZSE:300451, NYSE:EVH, NAS:QSII, NAS:TRHC, NAS:RCM, NAS:HSTM, LSE:EMIS, LSE:CRW, ASX:PME » details
Traded in other countries:CERN.Austria, CRE.Germany, CERN.Mexico, CERN.Switzerland, 0R00.UK,
Headquarter Location:USA
Cerner Corp is a supplier of healthcare information technology and offers software, professional services, medical device integration, remote hosting and employer health, and wellness services. The Domestic segment generates maximum revenue.

Cerner is a top-tier healthcare information technology supplier that helps its provider cleints to improve efficiency within thier complex healthcare operations. The company provides a wide range of software, hardware, and services to more than 9,000 facilities globally and has a footprint in roughly 30% of all U.S. hospitals.

Guru Investment Theses on Cerner Corp

Jeff Auxier Comments on Cerner Corp - Feb 06, 2018

Although revenues were up 8%, they came in below analysts’ expectations. Bookings were down 22.5% year over year due to several large contracts being delayed, causing it to come in below the company’s guidance. However, it could lead to all-time high levels of bookings once these deals are signed.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Cerner - May 09, 2017

Cerner (NASDAQ:CERN) is a leading healthcare information technology company which provides critical software to help automate hospitals and other healthcare providers. The stock traded down to a multiyear low valuation at year end providing for an attractive entry point to this high-quality enterprise.



From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Third Avenue Management Comments on Cerner - Feb 01, 2017

Cerner (NASDAQ:CERN) is a leading health care information technology company. We have long admired Cerner as it is a well-financed compounder, having compounded book value at an average rate of 16% over the past 10 years. Delays in customer adoption of healthcare Information Technology (IT) systems as regulatory mandates have lengthened, exacerbated by concerns about potential changes to the ACA and the impact on healthcare IT spend, have negatively pressured Cerner's common stock price down from over $67 to our initial purchase cost of approximately $48, giving us an opportunity to acquire shares of Cerner common stock at an attractive valuation.

Healthcare IT has been in the sweet spot of spending for hospitals as regulatory reform and increasingly complex regulatory requirements have driven a greater need for IT solutions. The ACA and Health Information Technology Economic and Clinical Health Act (HITECH) were established to transition the U.S. healthcare system from fee-for-service towards value-based outcomes, i.e., incentivizing hospitals and providers for increasing quality of care and patient outcomes rather than the volume of procedures performed. As part of this initiative, electronic health records systems were required and analytics and data collection to monitor outcomes is increasing. Cerner is one of the market leaders in these systems. Similar to other IT companies, services and software for the installed base of systems generates high-margin recurring revenue. Further, many legacy systems are in need of upgrades to enable them to meet the new regulatory requirements. Given its market leading position, Cerner has been gaining share and is well-positioned to continue to take share. In addition, there has been consolidation within the industry, including some vendors discontinuing products.

While uncertainty remains regarding the ultimate resolution of the ACA, we believe the benefit of increased efficiencies that enhanced IT systems provide, along with increasing use cases, e.g., population health, will continue to bode well for Cerner's business, enabling the company to grow and compound value over the longer-term.

From Third Avenue Management (Trades, Portfolio)'s fourth calendar quarter 2016 shareholder letter.

Check out Third Avenue Management,Martin Whitman latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 24.10
CERN's PE Ratio is ranked higher than
55% of the 1288 Companies
in the Global Health Information Services industry.

( Industry Median: 27.61 vs. CERN: 24.10 )
Ranked among companies with meaningful PE Ratio only.
CERN' s PE Ratio Range Over the Past 10 Years
Min: 14.92  Med: 35.21 Max: 54.94
Current: 24.1
14.92
54.94
Forward PE Ratio 24.10
CERN's Forward PE Ratio is ranked lower than
53% of the 318 Companies
in the Global Health Information Services industry.

( Industry Median: 24.04 vs. CERN: 24.10 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.10
CERN's PE Ratio without NRI is ranked higher than
56% of the 1279 Companies
in the Global Health Information Services industry.

( Industry Median: 27.94 vs. CERN: 24.10 )
Ranked among companies with meaningful PE Ratio without NRI only.
CERN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.92  Med: 35.21 Max: 54.94
Current: 24.1
14.92
54.94
Price-to-Owner-Earnings 28.21
CERN's Price-to-Owner-Earnings is ranked lower than
63% of the 749 Companies
in the Global Health Information Services industry.

( Industry Median: 27.98 vs. CERN: 28.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CERN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.58  Med: 35.26 Max: 73.18
Current: 28.21
18.58
73.18
PB Ratio 4.13
CERN's PB Ratio is ranked lower than
63% of the 1923 Companies
in the Global Health Information Services industry.

( Industry Median: 3.25 vs. CERN: 4.13 )
Ranked among companies with meaningful PB Ratio only.
CERN' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.75 Max: 6.95
Current: 4.13
2.05
6.95
PS Ratio 3.99
CERN's PS Ratio is ranked lower than
65% of the 1917 Companies
in the Global Health Information Services industry.

( Industry Median: 2.57 vs. CERN: 3.99 )
Ranked among companies with meaningful PS Ratio only.
CERN' s PS Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.55 Max: 7.51
Current: 3.99
1.67
7.51
Price-to-Free-Cash-Flow 27.44
CERN's Price-to-Free-Cash-Flow is ranked lower than
58% of the 689 Companies
in the Global Health Information Services industry.

( Industry Median: 28.70 vs. CERN: 27.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CERN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 23.24  Med: 41.14 Max: 490.81
Current: 27.44
23.24
490.81
Price-to-Operating-Cash-Flow 14.57
CERN's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 889 Companies
in the Global Health Information Services industry.

( Industry Median: 20.00 vs. CERN: 14.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CERN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.29  Med: 19.02 Max: 33.32
Current: 14.57
9.29
33.32
EV-to-EBIT 21.34
CERN's EV-to-EBIT is ranked lower than
53% of the 1329 Companies
in the Global Health Information Services industry.

( Industry Median: 20.79 vs. CERN: 21.34 )
Ranked among companies with meaningful EV-to-EBIT only.
CERN' s EV-to-EBIT Range Over the Past 10 Years
Min: 9  Med: 22.9 Max: 35.7
Current: 21.34
9
35.7
EV-to-EBITDA 12.94
CERN's EV-to-EBITDA is ranked higher than
58% of the 1441 Companies
in the Global Health Information Services industry.

( Industry Median: 16.23 vs. CERN: 12.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
CERN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 14.8 Max: 24.7
Current: 12.94
5.7
24.7
EV-to-Revenue 3.83
CERN's EV-to-Revenue is ranked lower than
63% of the 2002 Companies
in the Global Health Information Services industry.

( Industry Median: 2.59 vs. CERN: 3.83 )
Ranked among companies with meaningful EV-to-Revenue only.
CERN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 4.5 Max: 7.3
Current: 3.83
1.6
7.3
PEG Ratio 1.52
CERN's PEG Ratio is ranked higher than
62% of the 603 Companies
in the Global Health Information Services industry.

( Industry Median: 2.18 vs. CERN: 1.52 )
Ranked among companies with meaningful PEG Ratio only.
CERN' s PEG Ratio Range Over the Past 10 Years
Min: 0.82  Med: 2.13 Max: 3.8
Current: 1.52
0.82
3.8
Shiller PE Ratio 44.28
CERN's Shiller PE Ratio is ranked lower than
61% of the 359 Companies
in the Global Health Information Services industry.

( Industry Median: 39.15 vs. CERN: 44.28 )
Ranked among companies with meaningful Shiller PE Ratio only.
CERN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.87  Med: 67.98 Max: 94.06
Current: 44.28
34.87
94.06
Current Ratio 2.95
CERN's Current Ratio is ranked higher than
70% of the 1912 Companies
in the Global Health Information Services industry.

( Industry Median: 1.96 vs. CERN: 2.95 )
Ranked among companies with meaningful Current Ratio only.
CERN' s Current Ratio Range Over the Past 10 Years
Min: 1.75  Med: 2.7 Max: 5.87
Current: 2.95
1.75
5.87
Quick Ratio 2.93
CERN's Quick Ratio is ranked higher than
72% of the 1912 Companies
in the Global Health Information Services industry.

( Industry Median: 1.81 vs. CERN: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
CERN' s Quick Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.67 Max: 5.81
Current: 2.93
1.65
5.81
Days Inventory 6.53
CERN's Days Inventory is ranked higher than
69% of the 1183 Companies
in the Global Health Information Services industry.

( Industry Median: 17.94 vs. CERN: 6.53 )
Ranked among companies with meaningful Days Inventory only.
CERN' s Days Inventory Range Over the Past 10 Years
Min: 6.51  Med: 13.35 Max: 19.85
Current: 6.53
6.51
19.85
Days Sales Outstanding 72.61
CERN's Days Sales Outstanding is ranked lower than
54% of the 1642 Companies
in the Global Health Information Services industry.

( Industry Median: 68.90 vs. CERN: 72.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.04  Med: 73.12 Max: 91.82
Current: 72.61
66.04
91.82
Days Payable 86.49
CERN's Days Payable is ranked higher than
75% of the 1444 Companies
in the Global Health Information Services industry.

( Industry Median: 45.06 vs. CERN: 86.49 )
Ranked among companies with meaningful Days Payable only.
CERN' s Days Payable Range Over the Past 10 Years
Min: 47.89  Med: 95.2 Max: 115.48
Current: 86.49
47.89
115.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.90
CERN's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 1376 Companies
in the Global Health Information Services industry.

( Industry Median: -3.20 vs. CERN: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CERN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.2  Med: -1.5 Max: 4.3
Current: 0.9
-8.2
4.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 26.86
CERN's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 1165 Companies
in the Global Health Information Services industry.

( Industry Median: 7.81 vs. CERN: 26.86 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CERN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2  Med: 15.74 Max: 353.07
Current: 26.86
2
353.07
Price-to-Tangible-Book 7.39
CERN's Price-to-Tangible-Book is ranked lower than
67% of the 1612 Companies
in the Global Health Information Services industry.

( Industry Median: 4.78 vs. CERN: 7.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CERN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.83  Med: 5.37 Max: 14.44
Current: 7.39
0.83
14.44
Price-to-Intrinsic-Value-Projected-FCF 2.01
CERN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 789 Companies
in the Global Health Information Services industry.

( Industry Median: 2.28 vs. CERN: 2.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CERN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.47  Med: 2.88 Max: 7.23
Current: 2.01
1.47
7.23
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.92
CERN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
80% of the 129 Companies
in the Global Health Information Services industry.

( Industry Median: 1.82 vs. CERN: 0.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CERN' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.84  Med: 2.17 Max: 3.88
Current: 0.92
0.84
3.88
Price-to-Median-PS-Value 0.88
CERN's Price-to-Median-PS-Value is ranked higher than
66% of the 1595 Companies
in the Global Health Information Services industry.

( Industry Median: 1.14 vs. CERN: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CERN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.69 Max: 1.56
Current: 0.88
0.09
1.56
Price-to-Peter-Lynch-Fair-Value 1.50
CERN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
56% of the 374 Companies
in the Global Health Information Services industry.

( Industry Median: 1.65 vs. CERN: 1.50 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CERN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.93 Max: 11.5
Current: 1.5
0.46
11.5
Price-to-Graham-Number 2.81
CERN's Price-to-Graham-Number is ranked lower than
58% of the 920 Companies
in the Global Health Information Services industry.

( Industry Median: 2.64 vs. CERN: 2.81 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CERN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.56  Med: 2.86 Max: 5.64
Current: 2.81
0.56
5.64
Earnings Yield (Greenblatt) % 4.67
CERN's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 2098 Companies
in the Global Health Information Services industry.

( Industry Median: 1.99 vs. CERN: 4.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CERN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 4.4 Max: 11.1
Current: 4.67
2.8
11.1
Forward Rate of Return (Yacktman) % 18.08
CERN's Forward Rate of Return (Yacktman) % is ranked higher than
72% of the 834 Companies
in the Global Health Information Services industry.

( Industry Median: 10.67 vs. CERN: 18.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CERN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 15.6  Med: 18 Max: 21.2
Current: 18.08
15.6
21.2

More Statistics

Revenue (TTM) (Mil) $5,174.65
EPS (TTM) $ 2.53
Beta1.10
Volatility17.71%
52-Week Range $52.05 - 73.86
Shares Outstanding (Mil)342.10

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 5,425 5,822
EBIT (Mil $) 1,003 1,132
EBITDA (Mil $) 1,597 1,824
EPS ($) 2.13 2.47
EPS without NRI ($) 2.13 2.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.87%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}